Related Experiment Videos
Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives
Madhuri Devabhaktuni1, Sripal Bangalore
1Department of Medicine, Division of Cardiology, St Luke's Roosevelt Hospital, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Insights
A new fixed-dose combination pill for hypertension and dyslipidemia may improve patient adherence and cardiovascular outcomes. Simplifying medication regimens is key to managing these common risk factors effectively.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Hypertension and dyslipidemia frequently co-occur, significantly increasing coronary heart disease risk beyond additive effects.
- Despite proven benefits, achieving simultaneous reduction in blood pressure and cholesterol is successful in less than 10% of patients.
- Poor medication adherence, with up to 50% of patients discontinuing therapy, is a major barrier to managing these risk factors.
Purpose of the Study:
- To evaluate the efficacy and safety of a fixed-dose combination of amlodipine besylate and atorvastatin.
- To explore the potential of this combination therapy to improve medication compliance in patients with co-existing hypertension and dyslipidemia.
Main Methods:
- The study focused on a fixed-dose combination of amlodipine besylate (antihypertensive) and atorvastatin (statin).
- Evidence suggests that simplifying drug regimens and reducing pill burden enhances patient adherence.
Main Results:
- The fixed-dose combination is the first of its kind for these co-occurring conditions.
- The combination has demonstrated both efficacy and safety.
Conclusions:
- This fixed-dose combination offers a promising strategy to improve medication compliance.
- Enhanced adherence has the potential to improve cardiovascular outcomes in patients with hypertension and dyslipidemia.
Abstract:
Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular risk factors which together cause an increase in coronary heart disease-related events that is more than simply additive for anticipated event rates with each condition. Data have shown that even relatively small reductions in both blood pressure and cholesterol levels can lead to large reductions in the risk for cardiovascular events. However, though there are robust data on the beneficial effect of concomitant reduction in these risk factors, the reality is that this is achieved in <10% of patients. There is nonadherence with prescribed therapies with up to 50% of patients stopping their medications of their own volition for a variety of reasons. There is a reasonable evidence base to suggest that simplifying drug regimens and reducing pill burden will enhance patient adherence. The fixed-dose combination containing the antihypertensive agent amlodipine besylate and the statin atorvastatin is the first combination of its kind, which is both efficacious and safe and could potentially improve medication compliance, thereby improving the outcomes in these patients.
Related Concept Videos
01:26Atherosclerosis III: Management
01:27Coronary Artery Disease V: Interprofessional Care
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents